cefdinir (omnicef) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Cefdinir is an extended-spectrum, semisynthetic cephalosporin, for oral administration. As with other cephalosporins, bactericidal activity of cefdinir results from inhibition of cell wall synthesis. Cefdinir is stable in the presence of some, but not all, β-lactamase enzymes. Cefdinir is indicated for the treatment of: Community-Acquired Pneumonia, Acute Exacerbations of Chronic Bronchitis, Acute Maxillary Sinusitis, Pharyngitis/Tonsillitis and Uncomplicated Skin and Skin Structure Infections. Side effects include diarrhea, vaginal infections or inflammation, nausea, headache, and abdominal pain. Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox® TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%. As with other β-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir.   NCATS

Chemistry

  • SMILES: NC1=NC(=CS1)C(=N\O)\C(=O)N[C@H]2[C@H]3SCC(C=C)=C(N3C2=O)C(O)=O
  • InChIKey: RTXOFQZKPXMALH-GHXIOONMSA-N
  • Mol. Mass: 395.414
  • ALogP: -0.17
  • ChEMBL Molecule:
    cefdinir  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.0995 - $0.9073
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(6r,7r)-7-{2-(2-amino-thiazol-4-yl)-2-[(z)-hydroxyimino]-acetylamino}-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid | (6r,7r,z)-7-(2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido)-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid | 7-(2 (2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid | abbott brand of cefdinir | cefdiel | cefdinir | cefdinir monohydrate | cefdinirum | cefinir | cefnil | cefzon | cfdn | ci 983 | ci-983 | fk 482 | fk-482 | omnicef | pd 134393 | pd-134393

Organizations (26)

Research & Development (19)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (9)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (17)

Approved Indications (9)


 

Bronchitis, Chronic

Community-Acquired Infections (approved 2006)

Infections

Maxillary Sinusitis (approved 2006)

Otitis Media

Pharyngitis

Pneumonia

Staphylococcal Skin Infections (approved 2006)

Tonsillitis

Experimental Indications - Clinical Trial Phases 1-4 (11)


 

Anti-Bacterial Agents (Phase 4)

Appendicitis (Early Phase 1)

Bronchitis (Phase 4)

Community-Acquired Infections (Phase 4)

Dermatology (Phase 4)

Healthy Volunteers (Phase 4)

Mastitis (Phase 2/Phase 3)

Otitis Media ()

Pituitary Neoplasms (Phase 4)

Pneumonia (Phase 4)

Sinusitis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 24
  • # of Trial Organizations: 19

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue